Do you want to read an article? Please log in or register.
Kirsten Rat Sarcoma Virus Mutations Effect On Tumor Doubling Time And Prognosis Of Solid Dominant Stage I Lung Adenocarcinoma
Lung Cancer
RECOMMENDED
Related content
Lung Cancer
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
J Clin Med
Ruznic E, Klebermass M, Zellinger B, Langer B, Grambozov B, Purevdorj A, Karner J, Gruber G, Stana M, Minasch D, Kirchhammer K, Steffal C, Stranzl H, Moosbrugger R, Feurstein P, Dieckmann K, Zehentmayr F, ALLSTAR Group
doi: 10.3390/jcm14030945
Lung Cancer
Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma
Clin Lung Cancer
Masuda T, Katsumata S, Isaka M, Serizawa M, Kawata T, Asami M, Yamaguchi D, Matsushima K, Hayasaka K, Kojima H, Yokomakura N, Konno H, Nagashima T, Urakami K, Yamaguchi K, Ohde Y
doi: 10.1016/j.cllc.2025.04.009
Lung Cancer
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Lancet Respir Med
Shi Y, Wu L, Ji Y, Chen G, Li B, Bi M, Yang R, Miao L, Zhang G, Gao H, Sun L, Zhang M, Cang S, Sun M, Yao W, Pan Z, Cui J, Xiao Y, Wang Q, NCT04143607 Study Group
doi: 10.1016/S2213-2600(25)00121-3
Lung Cancer
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter Study
Clin Lung Cancer
Koster KL, Yohasenan S, Pakmak AS, Mark M, Metaxas Y, Lips C, Hitz F, Leskow P, Ludwig C, Putora PM, Glatzer M, Schneider T, Caviezel C, Mader T, Mousavi M, Blum M, Früh M, Joerger M
doi: 10.1016/j.cllc.2025.05.010
Lung Cancer
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
Lancet Respir Med
Shi Y, Guo Y, Li X, Wu L, Chen Z, Yang S, Bi M, Zhao Y, Yao W, Yu H, Wang K, Zhao W, Sun M, Zhang L, He Z, Lin Y, Shi J, Zhu B, Wang L, Pan Y, Shi H, Sun S, Wen M, Zhou R, Guo S, Han Z, Yi T, Zhang H, Cang S, Yu Z, Zhong D, Cui J, Fang J, Gao J, Li M, Ma R, Jiang M, Qin J, Shu Y, Ye F, Hu S, Li W, Lu H, Yang M, Yi S, Zhang Y, Fan Y, Ji H, Liu Z, Wang H, Zhou X, Zhang D, Peng J, Shen H, Gao F, Wang T, Zhou A
doi: 10.1016/S2213-2600(24)00417-X
Lung Cancer
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
Lung Cancer (Auckl)
Luo FX, Arter Z, Ou SI, Nagasaka M
doi: 10.2147/LCTT.S520833
Further Publications
EGFR-mutant lung adenocarcinoma transformed into small cell Lung cancer: A case report and literatures review
Respir Med Case Rep
Chen J, Huang H, Zhong P, Peng S, Zhu X, Ding X, Wang F, Kong P, Song T, Lu Z, Chen L
doi: 10.1016/j.rmcr.2025.102219
Pulmonary Fibrosis
Impact of availability of a highly effective Cystic Fibrosis treatment (elexacaftor/tezacaftor/ivacaftor) on lung transplant waitlist and lung transplantation trends in the US
Respir Med
Merlo C, Geiger JM, Wang Z, Lyden GR, Schladt DP, McGarry L
doi: 10.1016/j.rmed.2025.108171
RECOMMENDED
Lung Cancer
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Sci Rep
Claus J, De Smet D, Breyne J, Wesolowski J, Himpe U, Demedts I, Martens GA
doi: 10.1038/s41598-024-68350-6